Alain van Gool full professorAlain van Gool is professor Personalized Healthcare and heads the Translational Metabolic Laboratory at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. His professional background since 1991 is a mix of academia, pharmaceutical industry, applied research institutes, university medical centers. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development, and applications in translational scientific research.
Alain currently heads the 100 fte Translational Metabolic Laboratory of the Radboudumc, a mixed function research-diagnostic lab that specializes in genetic metabolic disorders and includes the Radboudumc proteomics, glycomics & metabolomics platforms. He also coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences), is co-initiator of Health-RI (the Netherlands Personalised Medicine and Health Research Infrastructure), is PI of the Biomarker Development Center and is chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine, thus contributing to the organization and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to several scientific advisory boards of start-up enterpreneurs, multinational companies, diagnostic organisations and conference organisers, and is part of editorial boards of several scientific journals.
Personal prizes & awards national & international
- Top Institute Pharma research grant, ‘The CSF proteome / metabolome as primary biomarker compartment for CNS disorders’, 2006-2011, Principle investigator of public-private partnership Organon, Solvay, TNO, RUN, RUG, UL, EMC, Eur 800.000.
- EU FP7 HEALTH research grant, “CarTarDis”, ‘Identification and validation of novel pharmaceutical drug targets for cardiovascular disease’, 2013-2017, Principle investigator and project coordinator of public-private partnership TNO, HMGU, KI, AZ, IHA, LUMC, CardioGenX, Polygene, Bioneer, Imabiotech, Morphisto, Umea University, MPC, Eur 5.973.000. www.cartardis.eu
- STW Perspectief research grant, ‘Biomarker Development Center’, 2013-2017, co-principle investigator, Eur 4.300.000. www.biomarkerdevelopmentcenter.nl
- EU H2020 grant, “PERFORM”, 2016-2020, ‘Personalised Risk assessment in febrile illness to Optimise Real-life Management across the European Union’, co-applicant, EUR 1.500.000 (of total project budget of EUR 14.000.000)
- Marie Curie ITN network “BrainMatTrain”, 2016-2019, ‘Development of biomaterial-based systems for Parkinson’s disease – an integrated pan-European approach’, co-applicant, Eur 3.995.080.
- COST action “CliniMARK”, 2017-2022, ‘Good biomarker practice’ to increase the number of clinically validated biomarkers’, co-applicant, EUR 750.000.
Field of study
Laboratory medicine, biomarkers, omics, bioanalytics, translational medicine, personalized healthcare
In the media
Technology center Mass spectrometry
The Technology Center for Mass Spectrometry offers high-level expertise in bioanalytical mass spectrometry combined with in-depth knowledge on biomedical and clinical applications, embedded in a cutting-edge clinical and fundamental research environment.read more